AtriCure, Inc. (ATRC)

Market Cap	1.58B
Revenue (ttm)	465.31M
Net Income (ttm)	-44.70M
Shares Out	49.49M
EPS (ttm)	-0.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	624,492
Open	32.17
Previous Close	31.74
Day's Range	31.62 - 32.37
52-Week Range	18.94 - 43.11
Beta	1.65
Analysts	Strong Buy
Price Target	48.50 (+51.47%)
Earnings Date	Apr 29, 2025

About ATRC

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user ...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Aug 5, 2005
• Employees: 1,300
• Stock Exchange: NASDAQ
• Ticker Symbol: ATRC
• Website: https://www.atricure.com

Financial Performance

In 2024, AtriCure's revenue was $465.31 million, an increase of 16.55% compared to the previous year's $399.25 million. Losses were -$44.70 million, 46.8% more than in 2023.

Analyst Forecast

According to 10 analysts, the average rating for ATRC stock is "Strong Buy." The 12-month stock price forecast is $48.5, which is an increase of 51.47% from the latest price.

Price Target

$48.5

(51.47% upside)

Analyst Consensus: Strong Buy